Biomarin

BioMarin (BMRN) Files NDA for Vosoritide to Treat Dwarfism
BioMarin (BMRN) Files NDA for Vosoritide to Treat Dwarfism
Yahoo/Zacks.com
Biomarin
FDA
achondroplasia
dwarfism
Flag link:
2 major FDA rejections leave some pharma investors worried about intensification of regulations
2 major FDA rejections leave some pharma investors worried about intensification of regulations
Beckers Hospital Review
FDA
drug approvals
drug development
Gilead Sciences
Biomarin
Flag link:
Is valrox dead?
Is valrox dead?
EP Vantage
Biomarin
hemophilia A
valrox
gene therapy
Roche
Pfizer
FDA
Flag link:
FDA gets out its red pen again, rejecting BioMarin's gene therapy valrox amid durability worries
FDA gets out its red pen again, rejecting BioMarin's gene therapy valrox amid durability worries
Fierce Biotech
Biomarin
FDA
valrox
hemophilia A
Flag link:
How Biomarin Beat Expectations in Q2
How Biomarin Beat Expectations in Q2
Motley Fool
Biomarin
earnings
Flag link:
Go or no go? Valuable drugs set for FDA decisions
Go or no go? Valuable drugs set for FDA decisions
EP Vantage
FDA
drug approvals
Novartis
inclisiran
Biomarin
valrox
Roche
risdiplam
GSK
belantamab mafodotin
Gilead Sciences
Galapagos
filgotinib
Flag link:
3 Biotech Stocks With Big Incoming Catalysts
3 Biotech Stocks With Big Incoming Catalysts
Motley Fool
FDA
GW Pharma
Epidiolex
filgotinib
Galapagos
Biomarin
valoctocogene roxaparvovec
Flag link:
With cell and gene therapy boom coming, experts at Novartis, Kite trumpet need for capacity: panel
With cell and gene therapy boom coming, experts at Novartis, Kite trumpet need for capacity: panel
Fierce Pharma
cell therapy
gene therapy
Novartis
Kite Pharma
Biomarin
Astellas
Flag link:
BioMarin Shares Additional Promising Phase I/II Data on Hemophilia A Treatment
BioMarin Shares Additional Promising Phase I/II Data on Hemophilia A Treatment
BioSpace
Biomarin
clinical trials
hemophilia A
valoctocogene roxaparvovec
Flag link:
BioMarin gene therapy shows sustained benefit in hemophilia A study
BioMarin gene therapy shows sustained benefit in hemophilia A study
Seeking Alpha
Biomarin
hemophilia A
clinical trials
gene therapy
valoctocogene roxaparvovec
Flag link:
BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies
BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies
Yahoo/PR Newswire
Biomarin
DiNAQOR
gene therapy
cardiomyopathy
Flag link:
BioMarin Blows Past Q1 Estimates, Projects 1st Year of Profitability in 2020
BioMarin Blows Past Q1 Estimates, Projects 1st Year of Profitability in 2020
Motley Fool
Biomarin
earnings
Flag link:
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
BioSpace
biosimilars
Amgen
Allergan
Roche
Rituxan
Bristol-Myers Squibb
ozanimod
risdiplam
Biomarin
valrox
Flag link:
BioMarin's Novel Treatment Promises to Disrupt Competitors
BioMarin's Novel Treatment Promises to Disrupt Competitors
Motley Fool
Biomarin
gene therapy
valrox
hemophilia A
Flag link:
FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review
FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review
Motley Fool
FDA
Biomarin
priority review
valrox
gene therapy
hemophilia A
Flag link:
Blockbusters in waiting: drug launches to watch in 2020
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Flag link:
Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World
Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World
Forbes
Biomarin
valrox
gene therapy
hemophilia A
Flag link:
BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy
BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy
Motley Fool
Biomarin
JPMHC 2020
drug pricing
valrox
hemophilia
Flag link:
BioMarin sets gene therapy sights beyond hemophilia
BioMarin sets gene therapy sights beyond hemophilia
BioPharma Dive
Biomarin
hemophilia
gene therapy
Flag link:
These 3 Biotech Stocks Could Be Top Stocks in 2020
These 3 Biotech Stocks Could Be Top Stocks in 2020
Motley Fool
Biomarin
Iovance
Immunomedics
Flag link:

Pages